Franck Morschhauser Selected Research

BEAM regimen

12/2014	Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
4/2011	(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Franck Morschhauser Research Topics

Disease

47	Lymphoma (Lymphomas) 12/2022 - 08/2003
43	Neoplasms (Cancer) 12/2022 - 08/2003
34	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 01/2003
32	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 02/2008
31	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2022 - 07/2007
26	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 08/2003
21	B-Cell Lymphoma (Lymphoma, B Cell) 11/2022 - 08/2010
15	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 08/2011
11	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 10/2022 - 09/2010
10	Neutropenia 01/2019 - 06/2003
8	Disease Progression 05/2019 - 02/2012
7	T-Cell Lymphoma (Lymphoma, T Cell) 01/2021 - 02/2005
6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2021 - 08/2011
5	Infections 01/2021 - 05/2006
4	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2018 - 04/2006
4	Thrombocytopenia (Thrombopenia) 01/2017 - 04/2015
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2022 - 09/2010
3	Hematologic Neoplasms (Hematological Malignancy) 10/2021 - 08/2014
3	Fever (Fevers) 01/2021 - 04/2015
3	Fatigue 01/2020 - 01/2019
3	Febrile Neutropenia 01/2018 - 06/2015
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2022 - 01/2014
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2021 - 07/2021
2	Residual Neoplasm 01/2021 - 11/2020
2	Carcinoma (Carcinomatosis) 01/2021 - 06/2016
2	Leukemia 11/2019 - 05/2006
2	Pathologic Complete Response 01/2018 - 12/2014
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 08/2017 - 08/2011
2	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 06/2017 - 02/2013
2	Nausea 04/2015 - 04/2015

Drug/Important Bio-Agent (IBA)

54	Rituximab (Mabthera)FDA Link 03/2022 - 01/2003
18	Lenalidomide (CC 5013)FDA Link 01/2022 - 09/2013
17	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 08/2003
17	obinutuzumabIBA 01/2022 - 05/2012
16	Pharmaceutical PreparationsIBA 01/2022 - 08/2003
15	Monoclonal AntibodiesIBA 01/2022 - 01/2003
14	Prednisone (Sone)FDA LinkGeneric 10/2022 - 04/2011
14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 04/2011
13	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 04/2007
7	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2022 - 03/2010
7	Agammaglobulinaemia Tyrosine KinaseIBA 03/2022 - 08/2014
7	ibrutinibIBA 03/2022 - 08/2014
7	ibritumomab tiuxetan (Zevalin)FDA Link 12/2014 - 07/2007
6	Brentuximab VedotinIBA 01/2021 - 07/2013
6	Yttrium-90IBA 12/2014 - 07/2007
5	Histone Deacetylase InhibitorsIBA 01/2022 - 01/2014
5	romidepsin (FK228)FDA Link 01/2022 - 02/2012
5	Bendamustine Hydrochloride FDA Link 11/2021 - 11/2013
5	venetoclaxIBA 11/2021 - 01/2019
5	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 10/2011
4	Biomarkers (Surrogate Marker)IBA 12/2022 - 02/2017
4	polatuzumab vedotinIBA 01/2022 - 06/2015
4	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 04/2011
3	Chimeric Antigen ReceptorsIBA 11/2022 - 01/2022
3	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022 - 01/2018
3	atezolizumabIBA 01/2022 - 01/2021
3	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 01/2018
3	tazemetostatIBA 01/2022 - 01/2020
3	idelalisibIBA 01/2021 - 01/2017
3	NivolumabIBA 01/2020 - 01/2017
3	copanlisibIBA 01/2020 - 12/2017
3	Hormones (Hormone)IBA 05/2018 - 02/2010
3	CytokinesIBA 01/2018 - 05/2007
3	pixantrone (BBR 2778)IBA 04/2015 - 08/2003
2	axicabtagene ciloleucelIBA 11/2022 - 07/2021
2	PlatinumIBA 03/2022 - 01/2022
2	tisagenlecleucelIBA 01/2022 - 07/2021
2	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 01/2019
2	ruxolitinibIBA 01/2021 - 01/2018
2	tirabrutinibIBA 01/2021 - 01/2020
2	EnzymesIBA 01/2021 - 04/2009
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2012
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 02/2011
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 12/2014
2	Phosphotransferases (Kinase)IBA 12/2020 - 11/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 11/2018
2	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2020
2	pembrolizumabIBA 01/2020 - 11/2019
2	acalabrutinibIBA 11/2019 - 01/2018
2	Chlorambucil (Leukeran)FDA Link 06/2017 - 02/2013
2	abexinostatIBA 01/2017 - 04/2015
2	Antineoplastic Agents (Antineoplastics)IBA 03/2016 - 04/2009
2	coltuximab ravtansineIBA 01/2016 - 01/2014
2	Melphalan (Alkeran)FDA LinkGeneric 12/2014 - 04/2011
2	InterferonsIBA 07/2013 - 12/2008
2	Mitoxantrone (Novantrone)FDA LinkGeneric 09/2010 - 08/2003
2	veltuzumabIBA 05/2010 - 07/2009

Therapy/Procedure

48	Therapeutics 11/2022 - 07/2007
35	Drug Therapy (Chemotherapy) 01/2022 - 02/2005
16	Stem Cell Transplantation 03/2022 - 07/2007
7	Immunotherapy 10/2021 - 07/2005
6	Cell Transplantation 01/2018 - 01/2017
6	Radioimmunotherapy 01/2014 - 07/2007
5	Transplantation 11/2019 - 04/2006
5	Bone Marrow Transplantation (Transplantation, Bone Marrow) 08/2018 - 12/2017
3	Induction Chemotherapy 01/2020 - 05/2006
2	Salvage Therapy 01/2021 - 12/2008
2	BEAM regimen 12/2014 - 04/2011
2	Intravenous Infusions 01/2014 - 09/2010
2	Autologous Transplantation 07/2013 - 08/2011